secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0001558370-24-008882
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics Phase 3 uproleselan misses primary OS endpoint; positive subgroup in primary refractory AML
--------------------------------------------------------------------------------

- Phase 3 missed primary endpoint: mOS 13.0 vs 12.3 months (HR 0.89; 95% CI 0.69-1.15), not statistically significant.
- In primary refractory AML (n=128), mOS improved to 31.2 vs 10.1 months (HR 0.58; 95% CI 0.37-0.91).
- Safety consistent with chemotherapy; no new adverse event signals.
- Company planning to engage regulators and NCI; Phase 2/3 study in frontline AML advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024008882/0001558370-24-008882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024008882/glyc-20240604x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer